biomarker, ok? certain endpoints are about understanding. if you're going to do a collective, it is understanding the pathway which will often be a whole series of interactions and alzheimer's is probably dozens or hundreds of proteins in a chain. it can be any number of them and each one will have the same effect because it is a chain effect and the weakest link is what causes the lead. you have to understand these mechanisms, that is why i am glad dartmouth is looking, they deserve a nobel or something. you are talking about mechanisms of action. if you contact those down in much smaller data sets, in fact, you don't really have to use of statistics at all. you can simply wake up and this is leading to that, leading to that and these are a lot of experience. i would also add that the tumor typically for the more common effects you can find 10,000 mutations in a cancerous and they can go crazy. they mutate in every possible direction. they just do it wildly. these analyses are sophisticated methods

lot of commentary out there that, ok, yes, it sounds great in theory to do this genomic work and biomarker work, but at the very basic analytical level, are we at the right level? are we mature enough with those analytical tools that we can actually say, ok, we are actually measuring accurately the genetic profile of the patient and being able to make the decisions on that basis? lynn: it comes down to don't throw the baby out with the bathwater. it comes down to the research component of it and the practical patient treatment component of it. right now, yes, it is not what hundred percent certain that it will respond to a receptor like pancreatic cancer. i have no evidence of that, but i have seen it work in other cancers. this patient has very little options. i see no reason to say, well, i really have got to check their genomic dna and they should that this is right. you know, it is the perfect standing in the way of the good and moving forward. in a research setting, yes, we should be doing that. in a research setting, you should be sequencing both the tumor as well as the normal dna,

successful prizable events would be things like identifying an alzheimer's biomarker or detect ing earlydetection techniques or repurposing existing drugs for treatment, things like this that would be established with a panel of experts. think of what we could achieve if people with all kinds of expertise combine their skills inside the government and outside the government to end alzheimer's. think of the progress we could make toward ending human suffering. my bill is s. 2067, the eureka act, and i have received support from researchers, including the mind center at the university of mississippi in my home state where we're doing innovative, groundbreaking achievements every day on alzheimer's. other organizations supporting this legislation, the eureka act, include the alzheimer's association, us against alzheimer's, the x prize foundation, the alzheimer's foundation of america, right focus foundation, leaders in alzheimer's disease otherwise known as lead, and eli lilly, all of these organizations and companies are supporting eureka. we already have not bipartisan cosponsorship of th